MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers.

MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers.
复制标题

DOI:
10.3390/ijms18102089
复制
发表时间:
2017-10-02
影响因子:
5.6
通讯作者:
Ahmad A
Ahmad A
中科院分区:
生物学2区
文献类型:
--
作者:
Farooqi AA;Tabassum S;Ahmad A

文献摘要

参考文献

被引文献

相似文献

MicroRNA-34a(miR-34a)是近年来备受关注的一种肿瘤抑制因子。它调节癌细胞的侵袭、转移和耐药性,也被评估为诊断和/或预后的生物标志物。已经确定了miR-34a的许多靶点,包括其他一些非编码RNA,人们认为这些无数靶点的调控突显了miR-34a在癌症进展和发病机制中的多种作用。来自临床前研究的看似吸引人的结果主张在临床试验中测试miR-34a。然而,获得的结果并不是非常令人鼓舞,有必要重新解释miR-34a在不同癌症中如何以一种上下文相关的方式发挥作用。在这篇综述中,我们试图总结与miR-34a对不同基因和非编码RNA的调控有关的最新证据,以及用于靶向传递基于miR-34a的治疗和模拟药物的纳米技术领域的进展。随着与miR-34a的肿瘤抑制功能相矛盾的数据的出现,了解miR-34a的准确功能非常重要,目的是确定其在个性化医学中的作用,并将这一知识用于识别可能从基于miR-34a的治疗中受益的个别患者。
MicroRNA-34a (miR-34a) is a tumor suppressor that has attracted considerable attention in recent years. It modulates cancer cell invasion, metastasis, and drug resistance, and has also been evaluated as a diagnostic and/or prognostic biomarker. A number of targets of miR-34a have been identified, including some other non-coding RNAs, and it is believed that the modulation of these myriads of targets underlines the versatile role of miR-34a in cancer progression and pathogenesis. Seemingly appealing results from preclinical studies have advocated the testing of miR-34a in clinical trials. However, the results obtained are not very encouraging and there is a need to re-interpret how miR-34a behaves in a context dependent manner in different cancers. In this review, we have attempted to summarize the most recent evidence related to the regulation of different genes and non-coding RNAs by miR-34a and the advances in the field of nanotechnology for the targeted delivery of miR-34a-based therapeutics and mimics. With the emergence of data that contradicts miR-34a’s tumor suppressive function, it is important to understand miR-34a’s precise functioning, with the aim to establish its role in personalized medicine and to apply this knowledge for the identification of individual patients that are likely to benefit from miR-34a-based therapy.
DOI: 10.1083/jcb.201110008
发表时间: 2012-04-16
期刊: The Journal of cell biology
影响因子: --
作者:
Kawai S;Amano A
通讯作者: Amano A
DOI: 10.1186/s12935-017-0431-9
发表时间: 2017
影响因子: 5.8
作者:
Chen AH;Qin YE;Tang WF;Tao J;Song HM;Zuo M
通讯作者: Zuo M
microRNA-34a 在乳腺癌中的诊断作用:系统评价和荟萃分析
DOI: 10.18632/oncotarget.15520
发表时间: 2017-04-04
期刊: Oncotarget
影响因子: --
作者:
Imani S;Zhang X;Hosseinifard H;Fu S;Fu J
通讯作者: Fu J
DOI: 10.1007/s10637-016-0407-y
发表时间: 2017-04
影响因子: 3.4
作者:
Beg MS;Brenner AJ;Sachdev J;Borad M;Kang YK;Stoudemire J;Smith S;Bader AG;Kim S;Hong DS
通讯作者: Hong DS
DOI: 10.1016/j.semcdb.2016.12.004
发表时间: 2017-07
影响因子: 7.3
作者:
Fanini F;Fabbri M
通讯作者: Fabbri M